Vertex Pharmaceuticals (BSP:VRTX34) Other Long-Term Liabilities : R$4,251 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Other Long-Term Liabilities?

Vertex Pharmaceuticals's other long-term liabilities for the quarter that ended in Mar. 2024 was R$4,251 Mil.

Vertex Pharmaceuticals's quarterly other long-term liabilities increased from Sep. 2023 (R$4,293 Mil) to Dec. 2023 (R$4,301 Mil) but then declined from Dec. 2023 (R$4,301 Mil) to Mar. 2024 (R$4,251 Mil).

Vertex Pharmaceuticals's annual other long-term liabilities increased from Dec. 2021 (R$1,715 Mil) to Dec. 2022 (R$3,597 Mil) and increased from Dec. 2022 (R$3,597 Mil) to Dec. 2023 (R$4,301 Mil).

Vertex Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Vertex Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Other Long-Term Liabilities Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Vertex Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Vertex Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Vertex Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines